MSU
PCRX icon

Mizuho Securities USA’s Pacira BioSciences PCRX Stock Holding History

Mizuho Securities USA’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-6,000
Closed -$261K – 152
2019
Q2 		$261K Sell
6,000
-18,500
-76% -$785K 0.01% 127
2019
Q1 		$932K Buy
+24,500
New +$956K 0.07% 87
2018
Q4 		– Sell
-23,500
Closed -$1.16M – 142
2018
Q3 		$1.16M Buy
23,500
+15,500
+194% +$670K 0.09% 86
2018
Q2 		$256K Sell
8,000
-19,300
-71% -$666K 0.03% 129
2018
Q1 		$850K Buy
27,300
+18,000
+194% +$641K 0.05% 81
2017
Q4 		$425K Buy
9,300
+1,600
+21% +$63.4K 0.02% 137
2017
Q3 		$289K Sell
7,700
-2,000
-21% -$80.5K 0.01% 163
2017
Q2 		$463K Hold
9,700
– – 0.02% 117
2017
Q1 		$456K Buy
+9,700
New +$419K 0.02% 109

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return